Analysts see little effect on the bottom lines of biopharma companies, as they stand to stave off tariff pressure and receive ...

The clearance brings an oral form of Novo’s Wegovy to market ahead of Lilly’s rival medication and kicks off the next phase ...

The startup’s filing comes during a broader biotech recovery that’s made some industry watchers optimistic IPOs could rebound ...

The overall leadership outlook was positive in a recent survey but varied between executives in the U.S. and those overseas.

Two pilot programs would tie Medicare costs and rebates in the U.S. to what’s paid in comparable countries. Elsewhere, AstraZeneca reported a setback and an “off the shelf” cell therapy showed promise ...

The results position Takeda, which acquired its therapy in one of the industry’s larger single-drug acquisitions, to challenge Bristol Myers Squibb’s Sotyktu.

The company’s valuation, which surged past $40 billion this year, fell by almost a fifth on a dimmer outlook for its closely followed lung disease medicine.

The Belgian biotech is still on the hunt for partners after reporting that its drug succeeded against an inflammatory skin and muscle disorder but missed in a lupus study.

Three decades ago, a scientist at the University of Texas named Bruce Beutler asked the U.S. government to grant him a patent for a new invention. Beutler, who would later win the Nobel Prize for his ...

Amgen is “batting .500 with this update,” Piper Sandler analyst Christopher Raymond wrote in a note to clients. While he called the rocatinlimab data “no bueno,” he said the potential for Uplizna as a ...

Lilly is testing out a new kind of drug delivery model with its program, aiming to help patients connect with physicians and then support them in obtaining any treatments that get prescribed. The ...